RELATED STUDY
A Cannabinoid 2-Selective Agonist Inhibits Allogeneic Skin Graft Rejection In Vivo
Key Findings: Using mixed lymphocyte reaction (MLR) as a model of organ and skin graft rejection in mice found that exposure to CB2 selective agonists prolongs skin graft rejection time, and presents a potential therapeutic target in organ transplant rejection prevention and autoimmune conditions.
Type of Study: Animal Study
Study Result: Positive
Research Location(s): United States
Year of Pub: 2021
Cannabinoids Studied: Tetrahydrocannabinol (THC), O-x Synthetic Cannabinoids, 2-Arachidonoyl Glycerol (2-AG), Endocannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2
Ligands Studied: Anti-inflammatory cytokines, Pro-inflammatory cytokines
Route of Administration: In vitro
Citation: Jayarajan S, et al. A Cannabinoid 2-Selective Agonist Inhibits Allogeneic Skin Graft Rejection In Vivo. Front Pharmacol. 2021; 12:804950. doi: 10.3389/fphar.2021.804950
Authors: Jayarajan S, Meissler JJ, Adler MW, Eisenstein TK
